CVTX CV Therapeutics (MM)

PALO ALTO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (NASDAQ:CVTX) today announced that seven abstracts featuring data from clinical studies with perindopril, including ASCOT, substudies from EUROPA, and PREAMI, will be presented at the European Society of Cardiology (ESC) Congress 2005, taking place in Stockholm, Sweden from September 3 through September 7, 2005. In addition, two abstracts featuring preclinical studies with ranolazine have been accepted. Ranolazine -- Inhibition of Late INa by Ranolazine Improves Left Ventricular Relaxation in a Model of Na+-Induced Ca2+ Overload. Sunday, September 4, 2005 from 3:30 p.m. to 4:30 p.m. Central European Summer Time (CEST). Poster Presentation #1081. -- Inhibition of Late INa by Ranolazine Reduces Ca2+ Overload and LV Mechanical Dysfunction in Ejecting Rat Hearts. Tuesday, September 6, 2005 from 11:45 a.m. to 12 noon CEST. Presentation # 2640. Perindopril ASCOT -- ASCOT-BPLA: The Anglo-Scandinavian Cardiac Outcomes Trial: Blood Pressure-Lowering Arm. Sunday, September 4, 2005 from 4:30 p.m. to 4:55 p.m. CEST. Presentation #753. PREAMI -- PREAMI: Perindopril and Remodeling in Elderly with Acute Myocardial Infarction. Sunday, September 4, 2005 from 11:44 a.m. to 12:01 p.m. CEST. Presentation #128. EUROPA -- Cost-Effectiveness of Perindopril Compared to Placebo to Prevent Cardio-Vascular Events in Stable Coronary Heart Disease. Monday, September 5, 2005 from 3:30 p.m. to 4:30 p.m. CEST. Poster Presentation #2297. -- Effects of Perindopril on Long-Term Clinical Outcome of Patients with Coronary Artery Disease and Preserved Left Ventricular Function -- The EUROPA Study. Tuesday, September 6, 2005 from 3:30 p.m. to 4:30 p.m. CEST. Poster Presentation #3489. -- Treatment Benefit by Perindopril in Patients with Stable Coronary Artery Disease at Different Levels of Risk. Wednesday, September 7, 2005 from 11:15 a.m. to 11:30 a.m. CEST. Presentation #3663. -- Effect of Perindopril in Patients with Stable Coronary Artery Disease: Results on Inflammatory and Thrombosis Markers of the Pertinent Study. Wednesday, September 7, 2005 from 11:45 a.m. to 12 noon CEST. Presentation #3665. Other -- Effects of Irbesartan and Perindopril on Endothelial Function and Inflammatory Process in Patients with Stable Angina Pectoris: Evidence for Anti-Inflammatory Properties. Monday, September 5, 2005 from 10 a.m. to 11 a.m. CEST. Poster Presentation #1714. Additional information regarding the European Society of Cardiology Congress 2005 can be accessed at http://www.escardio.org/. About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics currently has three programs in commercial or late-stage development: ACEON(R) (perindopril erbumine) Tablets, Ranexa(TM) (ranolazine) and regadenoson. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. The company co-promotes ACEON(R), an ACE inhibitor with enhanced tissue affinity, in the United States with Solvay Pharmaceuticals, Inc. ACEON(R) is indicated for the treatment of essential hypertension and the reduction of the risk of cardiovascular mortality or non- fatal myocardial infarction in patients with stable coronary artery disease. Ranexa is being developed as a novel potential treatment for chronic angina. Regadenoson is being developed with our partner in North America, Astellas Pharma US, Inc. for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Ranexa and regadenoson have not been approved for marketing by any regulatory authorities. Except for the historical information contained herein, the matters set forth in this press release, including statements as to development, clinical studies, regulatory review, and commercialization of products, are forward- looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, early stage of development; regulatory review and approval of our products; the conduct and timing of clinical trials; the dependence on collaborative and licensing agreements; commercialization of products; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2005. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements. DATASOURCE: CV Therapeutics, Inc. CONTACT: Investors: Christopher Chai, Vice President, Treasury and Investor Relations, +1-650-384-8560, or Media: John Bluth, Senior Director, Corporate Communications, +1-650-384-8850, both of CV Therapeutics, Inc. Web site: http://www.cvt.com/

Copyright